Mobile coupons are used by over 3,000 retailers at various scales and are believed to be a Rs 5-crore (Rs 50 million) business opportunity.
L&T plans to transfer the equity of L&T in their joint ventures with Mitsubishi Heavy Industries into L&T Power through a book transfer, if clauses for the re-tender remain the same, company executives told Business Standard.
Companies such as Larsen & Toubro and Bharat Heavy Electricals Ltd believe the undervalued renminbi (yuan) gives Chinese goods an unfair advantage in Indian markets.
Plans to set up an integrated pharma firm in a phased manner.
Mukesh Ambani's Reliance Industries Ltd may be one of the biggest producers of natural gas in the country, but its power foray is likely to be coal or renewable energy based. The company is planning to not only bid for ultra mega power projects but also go in for acquisition of the power plants, said industry sources.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
Private equity investor Actis is set to acquire a stake in infrastructure major GVK's power business for about Rs 1,000 crore, according to sources close to the development.
The Aditya Birla Group has received in-principle approval from the Kerala government to set up a Rs 4,000-crore (Rs 40 billion) IT and Biotech Knowledge Park and a branch of Birla Institute of Technology and Sciences (BITS) at Kozhikode.
Larsen & Toubro, India's largest engineering, construction and technology company, is aggressively expanding its footprint across various places abroad
Pfizer, the world's largest drug company, and Wyeth have sued Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.
Industry lobby, Mobile Marketing Association, along with other industry bodies, is submitting a proposal to the Telecom Regulatory Authority of India (Trai), opposing the possibility of a 'do-call' registry.
Investors with a 3-4 year time horizon should pick up telecom stocks.
Elder Pharma employs about 3,300 people in India, with about 2,700 professionals in marketing and sales. This recruitment will help Elder Pharma to have one of the largest drug sales force in India, like market leaders such as Cipla, Ranbaxy, Piramal Healthcare and Lupin.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
Japanese power companies, including Tokyo Electric Power Company and J-Power, seek to make their presence felt in India.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
Mobile phone companies wish to curtail toll-free calls from customers. According to a proposal being evaluated by the Telecom Regulatory Authority of India (Trai), calls made by customers to the phone company, other than complaints, will have to be charged.
If most of the top 10 Indian drug companies were less than Rs 500-crore (Rs 5-billion) turnover ones a decade earlier and were focused only on domestic business, now they are companies with annual businesses ranging from Rs 2,000-Rs 6,000 crore (Rs 20-60 billion) and with operations spanning 60-100 countries and employing 3,000-5,000 people.
An analysis of the growth rate of 15 leading drug companies for the third quarter of 2008-09 show excellent performances in domestic turf have been often marred by the poor show of their acquired assets.
The deal size could be in excess of Rs 2,000 crore, though this could not be verified. Sivasankaran had invested close to Rs 1,800 crore in 2007 to take a 41 per cent stake in Aamby Valley. The Sahara Group is the majority investor, with a 51 per cent stake.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances